(Alliance News) - Creo Medical Group PLC on Thursday said the National Institute for Health & Care Excellence in the UK has selected its Speedboat Inject product for assessment.
The Chepstow, Wales-based medical device company focused on surgical endoscopy said NICE selected Speedboat to be scoped and routed for guidance in respect of the endoscopic submucosal dissection of lower gastrointestinal lesions.
NICE is an executive non-departmental public body sponsored by the UK Department of Health & Social Care, providing national guidance and advice to improve health and social care.
Creo Medical said Speedboat Inject was selected for scoping and routing because NICE "anticipate[s] the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources."
Creo Medical said the selection follows a committee review of headline data and initiates a "multi-step" process whereby Speedboat's lower GI ESD clinical and economic evidence, along with other data, is evaluated by NICE.
Creo Medical said this may result in a specific NICE output such as medical technologies guidance.
"We are delighted that Speedboat Inject has reached this stage with NICE and the validation this provides given the progress we are already making in the UK," said Creo Medical Chief Executive Officer Craig Gulliford.
"We look forward to the outcome of the final stages of the review process as NICE concludes its work."
On Tuesday last week, Creo Medical said it reached its first in-human milestone for MicroBlate Flex, as part of a lung tissue ablation clinical study.
Its MicroBlate Flex device is a new soft tissue ablation tool, which is designed to ablate nodules and tumours in several tissue types.
The first in-human use of MicroBlate Flex was successfully completed at Royal Brompton Hospital, part of Guy's and St Thomas' NHS Foundation Trust.
This procedure was part of a multi-site clinical trial, with all patients having regular follow-up assessments post-procedure to monitor their progress.
Earlier in May, Creo Medical also reported that Royal Oldham Hospital became the latest NHS England hospital to utilise Speedboat Inject endoscopy device to prevent and treat bowel cancer.
It said the hospital also took delivery of multiple Croma Advanced Energy platform endoscope products and put in place weekly lists for multiple Speedboat Submucosal Dissection equipment.
Shares in Creo Medical were up 0.3% to 24.68 pence each in London on Thursday morning.
By Greg Rosenvinge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Creo Medical (CREO)